按病变部位比较PCI与CABG治疗左主干病变的荟萃分析
该荟萃分析纳入9项研究共6296例无保护左主干病变患者,按开口/干段与远端病变比较PCI与CABG的5年结局。开口/干段病变两者MACE与死亡无显著差异;远端病变PCI的MACE、死亡和血运重建风险均高于CABG,仅RCT分析中死亡获益未证实。
要点
- 开口/干段左主干病变:PCI与CABG的5年MACE和死亡无显著差异。
- 远端左主干病变:PCI的MACE、死亡和血运重建风险均高于CABG。
- RCT限定分析证实CABG在远端病变的MACE和血运重建获益,死亡获益未证实。
核心结论
- 远端无保护左主干病变患者中,CABG较PCI的MACE和血运重建发生率更低,而开口/干段病变两者结局无差异。
研究设计与样本
- 系统检索比较PCI与CABG治疗无保护左主干病变并按病变部位报告结局的随机对照试验和校正观察性研究。
- 共纳入9项研究(3项RCT、6项校正观察性研究),6296例患者,其中开口/干段2274例、远端4022例。
主要发现
- 5年随访时,开口/干段病变CABG与PCI的MACE无显著差异(HR 1.0,95%CI 0.79-1.27),死亡也无显著差异(HR 1.10,95%CI 0.84-1.46)。
- 远端病变PCI与MACE风险增加相关(HR 1.32,95%CI 1.10-1.58),死亡风险增加(HR 1.56,95%CI 1.19-2.04),血运重建风险增加(HR 2.07,95%CI 1.5-2.84)。
- 仅纳入RCT的分析证实CABG在远端病变的MACE和血运重建获益,但死亡获益未获证实。
关键数值与推荐
- 开口/干段病变5年MACE:CABG vs PCI的HR 1.0(95%CI 0.79-1.27);死亡HR 1.10(95%CI 0.84-1.46)。
- 远端病变5年MACE:PCI vs CABG的HR 1.32(95%CI 1.10-1.58);死亡HR 1.56(95%CI 1.19-2.04);血运重建HR 2.07(95%CI 1.5-2.84)。
临床怎么用
- 远端无保护左主干病变的心脏团队决策中,CABG在MACE和再次血运重建方面优于PCI。
- 开口/干段左主干病变可根据个体情况在PCI与CABG间选择,两者5年结局无显著差异。
局限性
- 纳入研究包含观察性设计,可能存在混杂偏倚。
- 仅RCT分析未证实远端病变CABG的死亡获益,该结论需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Comparative data after percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) for unprotected left main coronary artery (ULMCA) disease according to lesion site (ostial/shaft vs distal) are scant. The aim of this meta-analysis was to investigate outcomes after PCI or CABG for ULMCA disease according to lesion site. METHODS: Randomized controlled trials (RCTs) and adjusted observational studies that compared PCI versus CABG in patients with ULMCA disease and reported outcomes according to lesion site were systematically identified. Major adverse cardiovascular events (MACE; a composite of all-cause death, myocardial infarction, stroke, and repeat revascularization) and all-cause death were the co-primary end points. Individual components of MACE were secondary end points. Sensitivity analysis including RCTs only were performed for each outcome. RESULTS: Nine studies (3 RCTs, 6 adjusted observational), encompassing 6296 patients (2274 and 4022 treated for ostial/shaft or distal ULMCA, respectively) were included. At the 5-year follow-up, there were no significant differences between CABG and PCI for MACE, death, or any other secondary outcome for ostial/shaft ULMCA lesions (MACE: hazard ratio [HR], 1.0 [95% confidence interval (CI), 0.79-1.27]; death: HR, 1.10 [95% CI, 0.84-1.46]). For distal ULMCA, PCI was associated with an increased risk of MACE (HR, 1.32; 95% CI, 1.10-1.58), death (HR, 1.56; 95% CI, 1.19-2.04), and revascularization (HR, 2.07; 95% CI, 1.5-2.84). The benefit of CABG for MACE and revascularization was confirmed in the analysis limited to RCTs, whereas the benefit for mortality was not. CONCLUSIONS: Among patients with distal ULMCA disease, CABG is associated with lower incidence of MACE and revascularization compared with PCI, whereas no differences in outcomes were observed for ostial/shaft ULMCA disease.
引用
- De Filippo O, Di Franco A, Boretto P, et al. Percutaneous coronary intervention versus coronary artery surgery for left main disease according to lesion site: A meta-analysis. J Thorac Cardiovasc Surg. 2021. PMID: 34538641. doi:10.1016/j.jtcvs.2021.08.040
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。